"In the UK, patients still have to wait too long to access NICE recommended medicines on the NHS, but AHSNs will help speed this process up and help break down barriers to people getting innovative new treatments. The pharmaceutical industry has played a key role in helping to set up England’s 15 AHSNs by bringing expertise and insight in to how technologies are developed and disseminated in a commercial environment.
"AHSNs are unique because for the first time we will have a systematic network whose sole objective is to get the best ideas and treatments spread across the NHS as quickly and widely as possible. This is good news for patients and will also create a fertile environment for scientists and life science companies to research and develop new life changing medicines. We now look forward to help leading AHSNs in partnership with clinicians, academia, NHS managers and other healthcare stakeholders to ensure they are a success."
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811
Notes to editors
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.